#United States #Caris Life Sciences #Irving #Caris Detect #Achieve 1

Caris Life Sciences Achieves Significant Milestone in Cancer Detection

On February 26, 2026, Caris Life Sciences (NASDAQ: CAI), a leader in precision medicine and next-generation biotechnology, revealed interim results from the Achieve 1 study, a critical phase in their efforts to launch Caris Detect™, a multi-cancer early detection test. This breakthrough signifies a pivotal achievement in the company's mission to facilitate earlier cancer diagnosis through Whole Genome Sequencing and advanced artificial intelligence (AI).

The interim readout is a major stride towards improving cancer treatment outcomes by enabling physicians to identify malignancies at an earlier stage. By utilizing cutting-edge molecular profiling data, which includes insights from over one million processed cases and 50 billion molecular markers, Caris Detect aims to detect subtle biological signals linked to early-stage cancers with unprecedented accuracy.

Achieve 1 is structured to evaluate Caris Detect's capability of identifying multiple cancer types via a simple blood test. The study included a diverse patient cohort of 1,505 individuals, reflecting a higher cancer probability, as these subjects had either undergone screening or exhibited related symptoms. Notably, 22.5% of these individuals were monitored for approximately a year post-sampling, revealing that 121 participants who showed no signs or significant risk factors of cancer were not diagnosed within that period, showcasing the test's efficiency in distinguishing between healthy and at-risk subjects.

In this first phase, data was cross-validated using around 865 samples, with the validation process ongoing. Results are anticipated to be reported in the first quarter of 2026. The interim outcomes demonstrated encouraging metrics, which are summarized below:

Key Performance Data

Sensitivity

• - Stage I: 56.8% (n=266)
• - Stage II: 70.1% (n=137)
• - Stage III: 77.1% (n=105)
• - Stage IV: 99.1% (n=109)

This indicates that the test is notably effective in detecting cancers at various stages, particularly advanced stages, where timely intervention can significantly alter patient outcomes.

Specificity

The specificity rates were impressive, standing at 99.1% in the asymptomatic screening group and 95.3% in the broader undiagnosed cohort. With a comprehensive sample size of 2,122, the diversity and richness of the data further reinforce the potential value of Caris Detect in clinical settings.

Broader Implications

Dr. David Spetzler, President of Caris Life Sciences, emphasized the hypothesis that cancer is fundamentally a molecular disease. Through this lens, the company’s strategy encompasses a wide range of genomic alterations derived from Whole Genome Sequencing, rather than solely relying on the more limited epigenomic insights typically used in other early detection methods. This multifaceted approach enhances the performance metrics achieved, demonstrating the importance of incorporating extensive biological data in understanding cancer's molecular complexities.

As Caris continues to develop the next iteration of Caris Detect, the aim is to elevate the existing high-performance benchmarks further by integrating Whole Transcriptome Sequencing, which promises to refine diagnostic capabilities and therapeutic choices even more.

About Caris Life Sciences

Founded with the vision of harnessing precision medicine's potential, Caris Life Sciences is dedicated to transforming healthcare via innovative solutions. With a robust platform that fuses advanced AI, machine learning, and genomic insights, the company stands at the forefront of revolutionizing disease analysis and treatment pathways. Headquartered in Irving, Texas, with additional offices in major global cities, Caris is poised to impact healthcare delivery across the globe significantly.

Conclusion

The interim readout from the Achieve 1 study positions Caris Life Sciences at the leading edge of cancer detection technology. As ongoing trials unfold, the promise of Caris Detect could redefine early cancer diagnostics while improving patient outcomes through timely interventions. With its focus on comprehensive genomic understanding, Caris Life Sciences exemplifies the future of precision medicine, where innovation is harnessed in the fight against cancer, helping to save lives worldwide.